High-Purity Dapagliflozin Intermediate: 5-Bromo-2-Chloro-4'-Ethoxydiphenylmethane Manufacturer & Supplier

Discover the key building block for Dapagliflozin synthesis. We are a premier manufacturer and supplier of 5-Bromo-2-Chloro-4'-Ethoxydiphenylmethane (CAS 461432-23-5) in China, offering exceptional quality and competitive pricing for your pharmaceutical needs.

Get a Quote & Sample

Advantages of Sourcing Our Pharmaceutical Intermediates

Uncompromised Purity & Quality

We guarantee an assay of ≥99.0% for our 5-Bromo-2-Chloro-4'-Ethoxydiphenylmethane, ensuring consistent performance and high yields in your API manufacturing. When you purchase from us, you invest in reliable quality.

Strategic Supplier Partnership

Leverage our position as a key manufacturer of pharmaceutical intermediates in China. We offer stable supply chains and responsive customer service, making us an ideal partner for your production needs. Enquire about bulk price options.

Efficient Procurement Process

Our streamlined online platform and dedicated sales team make it easy to buy CAS 461432-23-5. We provide prompt responses to all inquiries, including requests for quotes and samples, facilitating your procurement journey.

Key Application: Dapagliflozin Synthesis

Primary Use as Dapagliflozin Intermediate

The primary application of 5-Bromo-2-Chloro-4'-Ethoxydiphenylmethane is its role as a crucial synthetic reagent in the production of Dapagliflozin, a vital medication for managing type 2 diabetes.

Enabling SGLT2 Inhibitor Development

This intermediate directly contributes to the development of potent and selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors, addressing a significant global health challenge.

Pharmaceutical API Manufacturing

As a high-quality Active Pharmaceutical Ingredient (API) intermediate, it plays a vital role in the complex chemical synthesis required for modern pharmaceutical manufacturing.

Research and Development

Researchers and development teams in the pharmaceutical sector rely on high-purity intermediates like this to explore novel synthetic routes and optimize existing processes for diabetic treatments.